Elta 90 Medical Research

What Elta 90 Medical Research does

Elta 90 Medical Research (legal name: ELTA 90 Medical Science) is a Romania-based, private medical diagnostics firm founded in 2010 and headquartered in Chiajna. The company's core offering is the deployment of Illumina-based Next Generation Sequencing (NGS) systems configured for whole genome HIV genotyping and drug resistance testing. Rather than operating as a pure hardware reseller, ELTA 90 packages its NGS instrumentation with HIV assays and bioinformatics software from strategic partner ABL Diagnostics, producing an integrated platform intended for national public-health surveillance programs. Its target customers are government health authorities and public laboratories requiring modernized molecular diagnostic infrastructure for population-level HIV drug resistance monitoring.

The company pursues an enterprise field sales motion aimed at public sector buyers — national ministries of health and public-health laboratories — and routes go-to-market primarily through public tenders and direct government contracting rather than commercial distribution. The go-to-market was validated by a tender awarded by the Montenegro Ministry of Health for state-level deployment of its whole genome HIV genotyping solution, representing the company's first disclosed national-scale contract. Revenue mechanics appear to combine (i) hardware sales of NGS systems into government health authorities and (ii) platform licensing and integration revenue from the bundled diagnostics stack, though specific pricing and contract values are not publicly disclosed.

Operationally the company is small (11-50 employees) and geographically concentrated in the Balkans (Montenegro confirmed). There is no disclosed funding history, M&A activity, or leadership team data in the available sources, and no AI/ML capabilities, patents, certifications, or awards are documented. As a result, the strategic narrative rests almost entirely on two signals: the ABL Diagnostics partnership and the Montenegro contract win, both of which are necessary but not sufficient indicators of durable scale.

Name

Elta 90 Medical Research

Legal name

ELTA 90 Medical Science

Website

https://elta90mr.ro

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Elta 90 Medical Research is a Romania-based private medical diagnostics firm that supplies Illumina-based NGS systems for whole genome HIV drug resistance genotyping, integrating ABL Diagnostics assays and bioinformatics software to serve government health authorities, with the Montenegro Ministry of Health as its first disclosed national-scale customer.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

Keywords

• HIV drug resistance testing
• Next generation sequencing
• Molecular diagnostic systems
• Genomic surveillance solutions
• Clinical diagnostic services

Headquarters

HQ city

Chiajna

HQ country

Romania

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. NGS Systems and Hardware: Supply of Illumina-based NGS systems to government health authorities and healthcare institutions for HIV drug resistance testing and surveillance programs
2. Platform Licensing and Integration: Integration and deployment of complete diagnostic platforms combining hardware systems with HIV assays and bioinformatics software under partnership arrangements

Go-to-market motion1 record

Core offering

ELTA 90 Medical Research provides Illumina-based Next-Generation Sequencing (NGS) systems as its core diagnostic platform for whole genome HIV genotyping and drug resistance testing. The company integrates its NGS hardware with ABL Diagnostics' HIV assays and bioinformatics software to deliver a complete, scalable platform for national HIV surveillance programs. Its primary customers are government health authorities and public health laboratories procuring modern molecular diagnostic infrastructure.

Product overview

ELTA 90 Medical Research provides Illumina-based Next-Generation Sequencing (NGS) systems as its core diagnostic platform. The company's primary offering centers on whole genome HIV genotyping solutions, which combine Illumina sequencing technology with ABL Diagnostics' HIV assays and bioinformatics software to create a scalable, high-precision platform for HIV drug resistance testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Illumina-based NGS Systems for HIV Genotyping

Quantifiable outcome

• Scalable high-precision platform for whole genome HIV genotyping deployed at national level

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature1 record

Partnerships

One partnership is on record.

• ABL DiagnosticscoreTechnology or Integration · 20 November 2025Strategic partnership where ABL Diagnostics contributes HIV assays and bioinformatics software, while ELTA 90 Medical Science provides Illumina-based NGS systems. Together they deliver a complete whole genome HIV genotyping solution for Montenegro's national HIV surveillance program. The combination creates a scalable, high-precision platform for state-level HIV drug resistance testing.

Scale indicators2 records

Recent moves2 records

Expansion highlights4 records

Broad incumbents

• Hologic: Hologic provides molecular diagnostics platforms and Panther systems used by public-health and hospital labs for viral load and infectious-disease testing, an adjacent incumbent in HIV-related molecular workflows.
• Eurofins Genomics: Eurofins operates a global network of genomics services laboratories offering sequencing and genotyping for clinical and public-health customers, representing a scaled incumbent alternative for HIV surveillance workloads.
• ARUP Laboratories: ARUP is a large reference laboratory providing specialty molecular and infectious-disease testing, including HIV-related assays, serving as a scaled alternative for HIV genotyping and resistance testing services.
• QIAGEN: QIAGEN provides sample-prep, assays, and bioinformatics for molecular diagnostics including infectious-disease and viral genotyping, competing with Elta 90's integrated HIV surveillance stack at the platform level.
• bioMérieux: bioMérieux offers microbiology and molecular diagnostics solutions, including infectious-disease assays and the BioFire platform, and is a relevant broad incumbent for national lab infrastructure tenders.
• Cepheid (Danaher): Cepheid's GeneXpert molecular systems are widely deployed in national infectious-disease programs and compete for the same public-health laboratory budgets that fund HIV surveillance upgrades.

Regional players

• Cerba Healthcare: Cerba Healthcare operates a European clinical specialty laboratory network with strong presence in France and adjacent geographies, providing infectious-disease and molecular diagnostics services to public and private healthcare customers.

Direct peers

• Vela Diagnostics: Vela Diagnostics offers NGS-based HIV-1 drug resistance testing and viral genotyping assays, directly competing for the same national surveillance and clinical-diagnostics tenders that Elta 90 targets.
• ABL Diagnostics: ABL Diagnostics provides HIV assays and bioinformatics software that Elta 90 integrates. They sit on the same HIV drug-resistance workflow and address the same national public-health surveillance use case.

Others

• Illumina: Illumina is the underlying sequencing platform provider whose NGS systems Elta 90 integrates. Illumina is a critical ecosystem enabler and a potential competitor if it sells directly to public-health customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/elta90mr
• LinkedInlinkedin.com/company/elta-90-medical-research

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elta 90 Medical Research